Piramal Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The inspection took place from 3 to 10 December 2025. At the end of the inspection, the US FDA issued a Form 483 with four observations, which relate to procedural enhancements and are expected to be categorized as VAI (Voluntary Action Indicated).

The company is preparing a detailed response to be submitted within the stipulated timelines and said it remains committed to the highest standards of compliance, working closely with the regulator to address all points raised.

Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.

The company reported a consolidated net loss of Rs 99.22 crore in Q2 FY26, compared with a net profit of Rs 22.59 crore recorded in Q2 FY25. Revenue from operations for the period under review declined 8.83% year-on-year (YoY) to Rs 2,043.72 crore.

Shares of Piramal Pharma rose 0.93% to Rs 173.40 on the BSE.

Powered by Capital Market - Live News

Piramal Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs 193, down 1.25% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 25609.05. The Sensex is at 83614.62, up 0.09%.Piramal Pharma Ltd has lost around 2.32% in last one month.Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has increased around 0.57% in last one month and is currently quoting at 22379.85, down 0.22% on the day. The volume in the stock stood at 12.78 lakh shares today, compared to the daily average of 35.33 lakh shares in last one month.

The benchmark November futures contract for the stock is quoting at Rs 193.39, down 1.49% on the day. Piramal Pharma Ltd tumbled 22.98% in last one year as compared to a 7.23% rally in NIFTY and a 0.81% spurt in the Nifty Pharma index.

The PE of the stock is 36.8 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Revenue from operations for the period under review declined 8.83% year-on-year (YoY) to Rs 2,043.72 crore. The YoY performance was impacted by inventory destocking by a customer in one large CDMO order.

EBITDA fell 44% YoY to Rs 224 crore in Q2 FY26 from Rs 403 crore in Q2 FY25. The EBITDA margin contracted to 11% in Q2 FY26 from 18% in the corresponding quarter last year.

The company reported a pre-tax loss of Rs 46.18 crore in the September 2025 quarter, compared with a profit before tax of Rs 120.12 crore in the same period last year.

On a half-year basis, the company reported a consolidated net loss of Rs 180.92 crore in H1 FY26, compared with a net loss of Rs 66.05 crore recorded in the same period last year, while revenue declined 5.13% year-on-year (YoY) to Rs 3,977.44 crore in H1 FY26.

Nandini Piramal, chairperson, Piramal Pharma, said ?YoY growth in the CDMO Business was primarily impacted by inventory destocking in one large on-patent commercial product. Inconsistent recovery in US biopharma funding along with uncertainties on global trade policies led to adverse impact on order inflows and customer decision making during H1FY26. However, in the months of September and October 2025, we have seen a significant pick up in biopharma funding, which if sustains, should lend impetus to increased RFPs and orders going forward. Also, we are seeing strong customer interest for onshore offerings which bodes well for the investments we have made in our overseas sites.

In our CHG business we further strengthened our leadership position in the US Sevoflurane market, while simultaneously working to obtain regulatory approvals for ex-US markets from our India plant. Our consumer business delivered healthy mid-teen growth, seamlessly collaborating with various stakeholders for smooth transition to new GST rates changes.?

Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.

The scrip rose 0.45% to currently trade at Rs 201.40 on the BSE.

Powered by Capital Market - Live News

Net loss of Piramal Pharma reported to Rs 99.22 crore in the quarter ended September 2025 as against net profit of Rs 22.59 crore during the previous quarter ended September 2024. Sales declined 8.83% to Rs 2043.72 crore in the quarter ended September 2025 as against Rs 2241.75 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News